TG Therapeutics To Present Pre-Clinical Data At American Association For Cancer Research Annual Meeting

TG Therapeutics Inc TGTX  would present preclinical data at the American Association for Cancer Research Annual Meeting. The meeting was being held until April 20 at the Emest N Morial Convention Center in Louisiana.

The company indicated that as part of an ongoing research collaboration with H Lee Motfitt Cancer Center and Research Institute, data was generated comparing TGR-1202 with the P12K-delta inhibitors idealisib, as well as, duvelisib in-vitro models. The company also pointed out some key conclusions from the poster.

TG Therapeutics' Executive Chairman and Interim CEO, Michael Weiss, said that "Many of the adverse events associated with existing PI3K-delta inhibitors such as colitis and hepatic toxicity, and most recently with opportunistic infections, are thought to be related to T-cell immune mediated mechanisms.'

He continued to comment that "This pre-clinical data now begins to elucidate key differences in the impact of these inhibitors on human T-cell subsets, which may explain the differentiated safety profile observed with TGR-1202 to date in the clinic. These data represent the first step in improving our understanding and we look forward to continuing our research collaboration with the team at Moffitt."

On Friday, shares of the company closed with a 2.71 percent gain.